Wolfe Research initiated coverage of Crinetics (CRNX) with a Peer Perform rating.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRNX:
- Crinetics upgraded to Buy from Hold at Jefferies
- Crinetics Pharmaceuticals Outlines 2025 Strategic Priorities
- Crinetics data ‘compelling’ despite safety concerns, says Leerink
- Crinetics CAH data ‘okay,’ but expectations were high, says Jefferies
- Crinetics Pharmaceuticals Advances Atumelnant After Successful Phase 2